CO5700740A2 - Preparacion solida - Google Patents

Preparacion solida

Info

Publication number
CO5700740A2
CO5700740A2 CO05043503A CO05043503A CO5700740A2 CO 5700740 A2 CO5700740 A2 CO 5700740A2 CO 05043503 A CO05043503 A CO 05043503A CO 05043503 A CO05043503 A CO 05043503A CO 5700740 A2 CO5700740 A2 CO 5700740A2
Authority
CO
Colombia
Prior art keywords
solid preparation
biguanide
active ingredient
preparation according
insulin
Prior art date
Application number
CO05043503A
Other languages
English (en)
Inventor
Masahiko Koike
Hiroyoshi Koyama
Naoru Hamaguchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32064024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5700740(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO5700740A2 publication Critical patent/CO5700740A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Una preparación sólida que tiene una fase, caracterizada porque un sensibilizador de insulina y un ingrediente activo (excepto sensibilizadores de insulina) sedispersan uniformemente, y una dureza de 100 hasta 400 N.2.- La preparación sólida de conformidad con la reivindicación 1, caracterizada porque el ingrediente activoes una biguanida.3.- La preparación sólida de conformidad con la reivindicación 2, caracterizada porque la biguanida es clorohidrato de metformina.4.- Una preparación sólida que tiene una fase, caracterizada porque un sensibilizador de insulina y un ingrediente activo (excepto sensibilizadores de insulina) que tienen una relación de tamaño medio de la misma hasta tamaño medio del sensibilizador de insulina de 0.5 hasta 15 se dispersan uniformemente.5.- La preparación sólida de conformidad con la reivindicación 4, caracterizada porque el ingrediente activo es una biguanida.6.- La preparación sólida de conformidad con la reivindicación 5, caracterizada porque la biguanida es clorohidrato de metformina.
CO05043503A 2002-10-07 2005-05-05 Preparacion solida CO5700740A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002294045 2002-10-07

Publications (1)

Publication Number Publication Date
CO5700740A2 true CO5700740A2 (es) 2006-11-30

Family

ID=32064024

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05043503A CO5700740A2 (es) 2002-10-07 2005-05-05 Preparacion solida

Country Status (26)

Country Link
US (1) US9101660B2 (es)
EP (1) EP1561472B2 (es)
JP (2) JP4236553B2 (es)
KR (2) KR20070119095A (es)
CN (1) CN100427143C (es)
AU (1) AU2003271103B2 (es)
BR (1) BR0315082A (es)
CA (1) CA2501587C (es)
CO (1) CO5700740A2 (es)
CR (1) CR7797A (es)
CY (1) CY1114863T1 (es)
DK (1) DK1561472T3 (es)
ES (1) ES2437072T5 (es)
HK (1) HK1080385A1 (es)
IL (1) IL167835A (es)
MA (1) MA27487A1 (es)
MX (1) MXPA05003668A (es)
NO (1) NO332993B1 (es)
NZ (2) NZ552559A (es)
PL (1) PL219608B1 (es)
PT (1) PT1561472E (es)
RU (1) RU2357757C2 (es)
SI (1) SI1561472T1 (es)
UA (1) UA80991C2 (es)
WO (1) WO2004030700A1 (es)
ZA (1) ZA200503507B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1588708A4 (en) 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CA2607419C (en) * 2005-04-26 2014-06-17 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
ES2576258T3 (es) * 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Preparación sólida que contiene un sensibilizador de insulina
KR101220643B1 (ko) * 2006-08-16 2013-01-14 알리코제약(주) 사포그릴레이트 함유 경구투여 형태의 약제
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP4832271B2 (ja) * 2006-12-11 2011-12-07 花王株式会社 粉末圧縮錠剤
EP2185138B1 (en) 2007-07-19 2016-09-07 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
WO2009030257A1 (en) * 2007-09-05 2009-03-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
CN101417130B (zh) * 2007-10-22 2010-10-06 鲁南制药集团股份有限公司 一种治疗ⅱ型糖尿病及其并发症的药物组合物
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2010084504A2 (en) * 2008-05-26 2010-07-29 Sun Pharmaceutical Industries Ltd. A stable, oral solid dosage form
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
WO2012012156A1 (en) * 2010-07-21 2012-01-26 Myomics, Inc. Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2441442A1 (en) * 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2465896C2 (ru) * 2011-01-20 2012-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция пролонгированного действия
CN105125539A (zh) * 2015-08-05 2015-12-09 浙江华海药业股份有限公司 吡格列酮二甲双胍片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CN1222317C (zh) * 1996-07-12 2005-10-12 第一制药株式会社 可迅速崩解的压模物质及其生产方法
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
WO1998057634A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JPH1160476A (ja) 1997-08-25 1999-03-02 Taisho Pharmaceut Co Ltd 圧縮固形組成物
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
EP1561458B1 (en) † 1998-07-28 2010-09-15 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
AU768994B2 (en) † 1998-11-12 2004-01-15 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CA2354053A1 (en) 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
EP1210087A2 (en) 1999-04-29 2002-06-05 City of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
FR2812547B1 (fr) 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2002087965A (ja) * 2000-09-14 2002-03-27 Lion Corp 口中崩壊性アスピリン含有錠剤
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20060286168A1 (en) 2002-07-11 2006-12-21 Masahiko Koike Process for producing coated preparation

Also Published As

Publication number Publication date
MA27487A1 (fr) 2005-08-01
PL376176A1 (en) 2005-12-27
ZA200503507B (en) 2006-08-30
AU2003271103B2 (en) 2008-02-28
NZ552559A (en) 2008-04-30
CA2501587C (en) 2008-06-03
UA80991C2 (en) 2007-11-26
KR100820609B1 (ko) 2008-04-10
JP2008208141A (ja) 2008-09-11
NO20052239L (no) 2005-06-29
BR0315082A (pt) 2005-08-16
EP1561472B2 (en) 2021-01-20
IL167835A (en) 2010-11-30
NO332993B1 (no) 2013-02-11
DK1561472T3 (da) 2013-11-11
EP1561472A1 (en) 2005-08-10
PL219608B1 (pl) 2015-06-30
ES2437072T5 (es) 2021-10-13
NO20052239D0 (no) 2005-05-06
SI1561472T1 (sl) 2014-01-31
JP2004149521A (ja) 2004-05-27
RU2357757C2 (ru) 2009-06-10
CN100427143C (zh) 2008-10-22
CR7797A (es) 2005-11-15
PT1561472E (pt) 2013-12-09
JP4236553B2 (ja) 2009-03-11
AU2003271103A1 (en) 2004-04-23
EP1561472B1 (en) 2013-10-02
EP1561472A4 (en) 2009-07-08
US9101660B2 (en) 2015-08-11
CA2501587A1 (en) 2004-04-15
KR20070119095A (ko) 2007-12-18
NZ539711A (en) 2007-09-28
MXPA05003668A (es) 2005-06-08
WO2004030700A1 (ja) 2004-04-15
US20050287207A1 (en) 2005-12-29
CN1717253A (zh) 2006-01-04
CY1114863T1 (el) 2016-12-14
KR20050070039A (ko) 2005-07-05
RU2005113999A (ru) 2005-12-10
HK1080385A1 (en) 2006-04-28
ES2437072T3 (es) 2014-01-08

Similar Documents

Publication Publication Date Title
CO5700740A2 (es) Preparacion solida
CY1120377T1 (el) Στερεη φαρμακευτικη δοσολογικη φαρμακοτεχνικη μορφη που περιεχει λοπιναβιρη
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
NO20022334D0 (no) Ny sammensetning og anvendelse
MEP49208A (en) Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
CY1105262T1 (el) Φαρμακευτικες συνθεσεις παρατεταμενης απελευθερωσης για την παρεντepικη χορηγηση βιολογικως δραστικων υδροφιλων ενωσεων
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
DE60312523D1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
ECSP066493A (es) Combinaciones sinérgicas de productos activos, fungicidas
NO20054681L (no) Farmasoytiske produkter
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
AR046824A1 (es) Composicion y aparato para la administracion transdermica.
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
AR109263A2 (es) Composición que comprende moxidectina
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
CO5540368A2 (es) Composicion de liberacion sostenida y proceso para producirla
AR046608A1 (es) Aparato para la administracion transdermica de agentes a base de nicotina
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
DE602004020488D1 (de) Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
FC Application refused